Continuing Medical Education: December 2007

December 2007
American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2803
Academic Journal
Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease Accreditation and Designation Statement: Blackwell Futura Media Services designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Awardâ„¢. Each physician should claim only those credits that he/she actually spent in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Related Articles

  • Continuing Medical Education Questions. Scolapio, James S.; Qadeer, Mohammed A; Levitzky, Benjamin; Marrero, Frank // American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2813 

    If you wish to receive credit for this activity, please refer to the Web site: Article Title:Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease

  • Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease. Turner, Dan; Grossman, Andrew B.; Rosh, Joel; Kugathasan, Subra; Gilman, Ashley R.; Baldassano, Robert; Griffiths, Anne M. // American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2804 

    BACKGROUND: The thiopurines, azathioprine and 6-mercaptopurine, are traditional first-line immunomodulatory agents in adult and pediatric Crohn's disease, but the comparative efficacy and safety of methotrexate have seldom been examined. We report outcomes with methotrexate treatment in...

  • Crohn's disease: Methotrexate can reduce prednisone requirements.  // Modern Medicine;May95, Vol. 63 Issue 5, p55 

    Presents an abstract of the article `Methotrexate for the Treatment of Crohn's Disease,' by B.G. Feagan, J. Rochon, et al published in the periodical `The New England Journal of Medicine,' dated February 2, 1995.

  • Mesalamine for Crohn's disease improves quality of life.  // Modern Medicine;Oct95, Vol. 63 Issue 10, p50 

    Presents an abstract of the article `Quality-of-Life Results of Double-Blind, Placebo-Controlled Trial of Mesalamine in Patients With Crohn's Disease,' by J.W. Singleton, S. Hanauer and M. Robinson which was featured in a science journal dated May 1995.

  • Natalizumab for active Crohn's disease. Ghosh, S. // Gut;Jul2003, Vol. 52 Issue 7, p1068 

    Discusses the article 'Natalizumab for Active Crohn's Disease,' by S. Ghosh, E. Goldin, F.H. Gordon et al, published in a 2003 issue of 'New England Journal of Medicine.'

  • Infliximab therapy in pediatric Crohn's disease: a review. Parashette, Kalyan Ray; Makam, Raghavendra Charan; Cuffari, Carmen // Clinical & Experimental Gastroenterology;2010, Vol. 3, p57 

    Anti-tumor necrosis factor alpha (TNF-α) therapy has re-defined our treatment paradigms in managing patients with Crohn's disease (CD) and ulcerative colitis. Although the ACCENT studies showed proven efficacy in the induction and maintenance of disease remission in adult patients with...

  • Letters to the Editor.  // Townsend Letter for Doctors & Patients;May2003, Issue 238, p99 

    Presents letters to the editor concerning issues related to medicine. Identification of foods that cause arthritis pain; Treatment of crohn's disease with acupuncture and herbal medicine; Capability of iodine supplementation to increase urinary excretion of fluoride and bromide.

  • Immunomodulation does not alter histology in resected Crohn’s disease. Frizelle, F. A.; Ing, A.; Gearry, R. B.; Whitehead, M.; Faragher, I. G.; Dobbs, B. // Techniques in Coloproctology;Dec2009, Vol. 13 Issue 4, p295 

    The use of immunomodulators (Azathioprine, 6-Mercaptopurine and Methotrexate) and biological agents (Infliximab and adalimumab) for the treatment of Crohn’s disease (CD) has increased in the recent years with the aim of treating the inflammatory component of the disease and hoping to...

  • Methotrexate.  // Reactions Weekly;Aug2014, Vol. 1513 Issue 1, p27 

    The article presents a case study of a 40-year-old man with Bell's palsy, a type of facial paralysis, after receiving the methotrexate for treatment of Crohn's disease and he was treated with prednisone and valaciclovir and he showed complete recovery.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics